<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01404923</url>
  </required_header>
  <id_info>
    <org_study_id>FMTO901</org_study_id>
    <nct_id>NCT01404923</nct_id>
  </id_info>
  <brief_title>Effectiveness of On-demand Meteospasmyl速 Use in Irritable Bowel Syndrome (IBS)</brief_title>
  <official_title>Assessment of On-demand MeteoSpasmyl速 Use Effectiveness in Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoires Mayoly Spindler</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoires Mayoly Spindler</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness of 2 IBS treatment strategies:

        -  Strategy A = MeteoSpasmyl速, on-demand therapy

        -  Strategy B = standard of care chosen by the physician
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Irritable Bowel Syndrome Quality Of Life Overall Score</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>Irritable Bowel Syndrome Quality of Life total score (IBSQoL) is a health-related Quality of Life (QoL) disease-specific scale adapted for French patients. Total score ranges from minimum=0 to maximum = 100 representing the best outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Improvement of the Total IBSQoL Scores</measure>
    <time_frame>Baseline and 6 Months</time_frame>
    <description>Improvement of the total IBSQoL scores from baseline to month 6 calculated in percentage</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">436</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>meteospasmyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti spasmodic agents</intervention_name>
    <description>best standard of care prescriptions</description>
    <arm_group_label>standard of care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alverine citrate, simeticone</intervention_name>
    <description>on-demand therapy</description>
    <arm_group_label>meteospasmyl</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female ambulatory patients, aged &gt;= 18 years

          -  with IBS as defined by Rome III criteria for more than 1 year and less than 10 years

          -  with a IBS-SSS between 175 and 400

        Exclusion Criteria:

          -  Acute diarrhea, bowel disorders due to an underlying cause

          -  Patient treated with MeteoSpasmyl速 within the past 6 months

          -  Recent history of gastro intestinal surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://onlinelibrary.wiley.com/doi/10.1111/ijcp.12333/full</url>
  </link>
  <results_reference>
    <citation>Ducrotte P, Grimaud JC, Dapoigny M, Personnic S, O'Mahony V, Andro-Delestrain MC. On-demand treatment with alverine citrate/simeticone compared with standard treatments for irritable bowel syndrome: results of a randomised pragmatic study. Int J Clin Pract. 2014 Feb;68(2):245-54. doi: 10.1111/ijcp.12333. Epub 2013 Oct 21.</citation>
    <PMID>24147869</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2011</study_first_submitted>
  <study_first_submitted_qc>July 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2011</study_first_posted>
  <results_first_submitted>October 14, 2014</results_first_submitted>
  <results_first_submitted_qc>November 3, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 4, 2014</results_first_posted>
  <last_update_submitted>November 3, 2014</last_update_submitted>
  <last_update_submitted_qc>November 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parasympatholytics</mesh_term>
    <mesh_term>Alverine</mesh_term>
    <mesh_term>Mebeverine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Meteospasmyl</title>
          <description>alverine citrate, simeticone: on-demand therapy</description>
        </group>
        <group group_id="P2">
          <title>Standard of Care</title>
          <description>anti spasmodic agents: best standard of care prescriptions</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="222"/>
                <participants group_id="P2" count="214"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="199"/>
                <participants group_id="P2" count="197"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Meteospasmyl</title>
          <description>alverine citrate, simeticone: on-demand therapy</description>
        </group>
        <group group_id="B2">
          <title>Standard of Care</title>
          <description>anti spasmodic agents: best standard of care prescriptions</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="222"/>
            <count group_id="B2" value="214"/>
            <count group_id="B3" value="436"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.8" spread="14.9"/>
                    <measurement group_id="B2" value="55.1" spread="16.2"/>
                    <measurement group_id="B3" value="54.4" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="222"/>
                    <measurement group_id="B2" value="214"/>
                    <measurement group_id="B3" value="436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Irritable Bowel Syndrome Quality Of Life Overall Score</title>
        <description>Irritable Bowel Syndrome Quality of Life total score (IBSQoL) is a health-related Quality of Life (QoL) disease-specific scale adapted for French patients. Total score ranges from minimum=0 to maximum = 100 representing the best outcome.</description>
        <time_frame>Baseline and 6 months</time_frame>
        <population>The efficacy population included all patients with a calculable IBSQoL score at baseline and at least one of the following visit, i.e 173 and 167 patients, respectively in Meteospasmyl and standard of care group.</population>
        <group_list>
          <group group_id="O1">
            <title>Meteospasmyl</title>
            <description>alverine citrate, simeticone: on-demand therapy</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>anti spasmodic agents: best standard of care prescriptions</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Irritable Bowel Syndrome Quality Of Life Overall Score</title>
          <description>Irritable Bowel Syndrome Quality of Life total score (IBSQoL) is a health-related Quality of Life (QoL) disease-specific scale adapted for French patients. Total score ranges from minimum=0 to maximum = 100 representing the best outcome.</description>
          <population>The efficacy population included all patients with a calculable IBSQoL score at baseline and at least one of the following visit, i.e 173 and 167 patients, respectively in Meteospasmyl and standard of care group.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8" spread="1.1"/>
                    <measurement group_id="O2" value="8.4" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.4</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Improvement of the Total IBSQoL Scores</title>
        <description>Improvement of the total IBSQoL scores from baseline to month 6 calculated in percentage</description>
        <time_frame>Baseline and 6 Months</time_frame>
        <population>The efficacy population included all patients with a calculable IBSQoL score at baseline and at lesat one of the following visit, i.e 173 and 167 patients, respectively in Meteospasmyl and standard of care group.</population>
        <group_list>
          <group group_id="O1">
            <title>Meteospasmyl</title>
            <description>alverine citrate, simeticone: on-demand therapy</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>anti spasmodic agents: best standard of care prescriptions</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Improvement of the Total IBSQoL Scores</title>
          <description>Improvement of the total IBSQoL scores from baseline to month 6 calculated in percentage</description>
          <population>The efficacy population included all patients with a calculable IBSQoL score at baseline and at lesat one of the following visit, i.e 173 and 167 patients, respectively in Meteospasmyl and standard of care group.</population>
          <units>% of improvement of IBSQoL total scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="173"/>
                <count group_id="O2" value="167"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5" spread="49.1"/>
                    <measurement group_id="O2" value="18.6" spread="37.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>Four patients in standard of care group were excluded because no data available (Lost of follow up)</desc>
      <group_list>
        <group group_id="E1">
          <title>Meteospasmyl</title>
          <description>alverine citrate, simeticone: on-demand therapy</description>
        </group>
        <group group_id="E2">
          <title>Standard of Care</title>
          <description>anti spasmodic agents: best standard of care prescriptions</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sigmoiditis abcess intestinal</sub_title>
                <description>sigmoid diverticulitis abscess. Unexpected, not related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <description>Cancer of the cervix. Unexpected, not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <description>Kidney tumor. Unexpected, not related.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="222"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>transient ischaemic attack</sub_title>
                <description>Pre-existing hypertension and diabetes.Unexpected and not related to study drug</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>pyloroplasty</sub_title>
                <description>pre-existing disabling disorders of gastric emptying requiring surgery. Unexpected and not related to study drug.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Electrical cardioversion</sub_title>
                <description>Medical history of hypertension, atrial fibrillation. Unexpected not related.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="222"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="222"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea, diarrhea, heartburn</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="222"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical trials Manager</name_or_title>
      <organization>Laboratoires Mayoly Spindler</organization>
      <phone>33 134805555</phone>
      <email>contact_essais_cliniques@mayoly-spindler.fr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

